Advertisement

Product › Details
Opdivo®
![]() |
Next higher product group | nivolumab |
![]() |
Status | 2014-12-01 registration start |
![]() |
Organisation | Bristol-Myers Squibb Co. (BMS) (NYSE: BMY) |
Group | Bristol-Myers Squibb (BMS) (Group) | |
Organisation 2 | Ono Pharmaceutical Co., Ltd. (TSE: 4528) | |
Group | Ono Pharmaceutical (Group) | |
Record changed: 2021-03-23 |
Advertisement

More documents for Opdivo®
- [1] Biocartis Group N.V.. (3/5/20). "Press Release: Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla MSI test in China". Mechelen....
- [2] ESMO. (9/18/19). "Press Release: Electronic Nose Can Sniff Out Which Lung Cancer Patients Will Respond to Immunotherapy [Annals of Oncology Press Release]"....
- [3] Bristol-Myers Squibb Company. (1/3/19). "Press Release: Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company". New York, NY & Summit, NJ....
- [4] Achilles Therapeutics Ltd.. (9/19/18). "Press Release: Achilles Today Announces that It has Appointed Senior Pharmaceutical Executive Michael F. Giordano, M.D., to Its Board of Directors". Stevenage....
- [5] Bavarian Nordic A/S. (7/11/18). "Press Release: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer". Copenhagen....
- [6] Bavarian Nordic A/S. (3/8/18). "Press Release: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer". Copenhagen....
- [7] Agilent Technologies Inc.. (9/19/17). "Press Release: Agilent Announces Expanded Use of Cancer Diagnostic in the United States. Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications". Santa Clara, CA....
- [8] Agilent Technologies Inc.. (6/16/17). "Press Release: Agilent Technologies Announces Expanded Use of Cancer Diagnostic in Europe". Santa Clara, CA....
- [9] Bristol-Myers Squibb Company. (6/2/17). "Press Release: European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platin...
- [10] Transgene S.A.. (4/25/17). "Press Release: Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer". New York, NY & Stras...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top